Skip to main content
Smart Investors Daily
EC

NASDAQ · ECOR

electroCore, Inc.

Healthcare · Medical - Devices

$5.25

Down-$0.41 (-7.81%)

Updated Nov 17, 2026, 1:36 AM

SID Score

3.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
39.09M
P/E ratio
-3.07
Dividend yield
0.00%
52-week range
$4.37 – $12.70
Volume
290.85K
Avg. volume
53.04K

Price performance · ECOR

ECOR price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 13, 2026

ECOR closed at $5.25 after 20 trading sessions, down 31.19% for the selected period.

Last close
$5.25
Period change
-31.19%
Period low
$5.25
Period high
$8.80
Daily close
View OHLC price history
ECOR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 13, 2026$5.42$5.5558$4.37$5.25290.85K
Nov 12, 2026$7.67$7.9212$4.92$5.29619.62K
Nov 11, 2026$7.67$8.3237$7.62$7.7163.39K
Nov 10, 2026$7.30$7.93$7.095$7.72100.92K
Nov 9, 2026$7.41$8.037$7.03$7.18421.99K
Nov 6, 2026$8.93$8.93$7.25$7.25129.76K
Nov 5, 2026$8.12$8.9999$7.895$8.80185.65K
Nov 4, 2026$7.1905$8.59$7.1905$8.40239.33K
Nov 3, 2026$6.9943$7.41$6.9301$7.23126.04K
Nov 2, 2026$7.57$8.17$7.08$7.1694.13K
Oct 30, 2026$7.76$8.54$7.495$7.5265.78K
Oct 29, 2026$8.47$8.56$8.11$8.1133.03K
Oct 28, 2026$7.76$8.56$7.65$8.4245.04K
Oct 27, 2026$7.58$7.90$7.47$7.7662.14K
Oct 26, 2026$7.07$7.57$7.07$7.4471.32K
Oct 23, 2026$7.25$7.50$7.00$7.05131.2K
Oct 22, 2026$7.13$7.7199$7.13$7.4138.07K
Oct 21, 2026$7.9473$7.9473$7.27$7.3553.14K
Oct 20, 2026$7.52$8.00$7.40$7.4955.21K
Oct 19, 2026$7.82$8.1755$7.40$7.6370.69K

Latest ECOR news

The latest Smart Investors Daily articles mentioning ECOR.

ECOR research

Overview

Company profile and research snapshot.

Company profile

electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
ECOR recent ratings
DateFirmRatingTarget
Jan 26, 2026HC Wainwright & Co.Buy—
Mar 13, 2025Ladenburg ThalmannBuy—
Mar 13, 2025HC Wainwright & Co.Buy—
Dec 18, 2024HC Wainwright & Co.Buy—
Mar 14, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 12, 2026

Randomized Study of Non-Invasive Autonomic Neuromodulation for Long COVID Published Online in Neuromodulation

Randomized, open-label, hypothesis-generating study (541 participants enrolled; 250 met final analysis criteria) evaluated two proprietary non-invasive neuromodulation technologies, electroCore’s cervical vagus nerve stimulation and Sonocea Sonic Augmentation Technology™ (SAT)ROCKAWAY, N.J., Nov. 12, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced that results from a randomized, open label-controlled

Yahoo · Nov 5, 2026

electroCore to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

ROCKAWAY, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, taking place on Wednesday, November 11, 2026, at The Westin New York Grand Central in New York City. Joshua Lev, Co-Chief Executive Officer, President and Chief Financial Officer, will present at the conference and host

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.